News Industry News U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin) January 24, 2016
News Industry News Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial September 18, 2015
News Industry News Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions June 05, 2015